Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Venous Thromboembolism × betrixaban × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 1

Interventions

Dalteparin 8 Rivaroxaban 6 apixaban 5 Heparin, Low-Molecular-Weight 5 Tinzaparin 4 Enoxaparin 4 bemiparin 2 abelacimab 2 Warfarin 2 MAA868 2 Aspirin 2 reviparin 1 edoxaban 1 certoparin 1 betrixaban 1 argatroban 1 acarboxyprothrombin 1 Phenprocoumon 1 Nadroparin 1 N(4)-oleylcytosine arabinoside 1 Dabigatran 1 Acenocoumarol 1 AVE 5026 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed

7,513 enrolled 18 charts 1 FDA

Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡